Pharmacokinetic assessment of tacrolimus in combination with deoxyschizandrin in rats

• DOI: 10.3389/fphar.2024.1344369
• Publication Date: 2024-05-23T04:23:52Z
• Authors: Jianguo Sun; Zhipeng Wang; Na Liu; Zhijun Liu; Lili Cui; Xia Tao; Wansheng Chen; Shouhong Gao; Zhijun Wu
• Keywords: Capsule

Background Tacrolimus (Tac) is commonly used for postoperative immunosuppressive therapy in transplant patients. However, problems, example, low bioavailability and unstable plasma concentration, persist a long time, Studies have reported that the deoxyschizandrin could effectively improve these but pharmacokinetic parameters (PKs) of Tac combined with are still unknown. Method In this study, an UHPLC-MS/MS method has been established simultaneous quantitation deoxyschizandrin. The PKs influenced by different doses after single multiple administrations were analyzed, impact Wuzhi capsule on compared. Result modified rapid quantification within 2 min using bifendatatum as internal standard (IS). All items successfully validated. C max increased from 148.27 ± 23.20 to 229.13 54.77 ng/mL rats 12 days. After co-administration 150 mg/mL deoxyschizandrin, had earlier T greater AUC 0–t , 14.26 4.73 54.48 14.37 95.10 32.61 315.23 92.22 h/ng/mL, respectively; relationship was positively proportional dosage addition, compared capsule, same dose better effective along more stable overall PKs. Conclusion An validated detection Tac. Deoxyschizandrin vivo exposure level stability Tac, besides, effect than dose.